Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Phase 3, Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Efficacy and Safety of Maintenance Treatment and Flare Reduction With Crisaborole Ointment, 2%, Once Daily Over 52 Weeks in Pediatric and Adult Participants (Ages 3 Months and Older) With Mild-to-Moderate Atopic Dermatitis, Who Responded to Twice Daily Crisaborole Ointment, 2%, Treatment
Brief Summary: This study will evaluate crisaborole therapy once daily (QD) as a long-term topical maintenance therapy for the reduction of flare in responders to crisaborole twice daily (BID) treatment.


Options:
A: Inclusion Criteria:

* Age 18 years or above
* European ancestry
* AD diagnosis according to Hanifin \& Rajka criteria
* AD for at least 3 years
* AD that is moderate-to-severe defined as an EASI score of ≥ 7
* AD in the sampled location that has an TLSS score of ≥ 5

EXCLUSION CRITERIA:

* Current or present systemic immunosuppressant and/or biological treatment for the past 4 weeks
* Evidence of other concomitant inflammatory skin conditions (e.g., psoriasis or contact dermatitis)
* Evidence of active skin infection that warrants treatment at screening or baseline visit
* Systemic or topical antibiotics in the preceding past 4 weeks
* Use of disinfectants, bleach and potassium permanganate baths at least 2 weeks before sampling
* UV therapy within the last 3 weeks, or pronounced exposure to sunlight in the preceding 2 weeks
* History of any condition (e.g. bleeding diathesis) that may predispose the patient to complications associated with the planned skin biopsy procedures
* Other clinically significant medical disease that is uncontrolled despite treatment that is likely, in the opinion of the investigator, to impact the patient's ability to participate in the study or to impact the study pharmacodynamic, or safety assessments
* Decreased kidney function (GFR under 60 ml/min)
* Tendency to formation of keloid scars
* Penicillin or mometasone futurate allergy or intolerance
* Pregnancy
* Breast feeding
* Body weight ≤ 40 kg
* AD only located in the face or intimate regions
B: Inclusion Criteria:

* Male or female
* 3 months of age and older
* Confirmed diagnosis of atopic dermatitis according to Hanifin and Rajka criteria
* Minimum of 5% BSA affected by atopic dermatitis
* ISGA score of Mild (2) or Moderate (3)

Exclusion Criteria:

- Has any clinically significant medical disorder, condition, or disease (including active or potentially recurrent non AD dermatological conditions and known genetic dermatological conditions that overlap with AD, such as Netherton syndrome).
C: Inclusion Criteria:

* Confirmed diagnosis of active atopic dermatitis (AD) with at least 6 month history prior to Screening and that has been clinically stable for 1 month.
* Investigator's Static Global Assessment (ISGA) of 2 (mild) or 3 (moderate) at Baseline.
* Body surface area (BSA) covered with AD of at least 0.5% and no more than 10% at Baseline, calculation excluding face, scalp, axilla, genitals, groin area, palms, back of the hands, and soles.
* Two lesions of AD at least 3 cm x 3 cm in size and at least 5 cm apart, with identical Lesion ISGA score of greater than/equal to 3.

Exclusion Criteria:

* Clinically infected AD or requires high potency topical corticosteroids or systemic (oral/injectable) corticosteroids to manage AD.
* History of angioedema or anaphylaxis to topical products or known sensitivity to components of crisaborole ointment 2%.
* History of cancer (except squamous or basal cell carcinoma or carcinoma in situ of the skin).
* Previous treatment with any topical or systemic PDE4 inhibitor unless stopped for the reason of lack of efficacy.
D: Inclusion Criteria:

* Males or females 2 years and older
* Has a clinical diagnosis of Atopic Dermatitis (AD) according to the criteria of Hanifin and Rajka
* Has AD involvement ≥ 5% Treatable %BSA (excluding the scalp)
* Has an ISGA score of Mild (2) or Moderate (3) at Baseline/Day 1
* All female subjects of childbearing potential must use acceptable methods of contraception from the Screening Visit continuously until 30 days after stopping study drug

Exclusion Criteria:

* As determined by the study doctor, a medical history that may interfere with study objectives
* Unstable AD or any consistent requirement for high potency topical corticosteroids
* History of use of biologic therapy (including intravenous immunoglobulin)
* Recent or anticipated concomitant use of systemic or topical therapies that might alter the course of AD
* Recent or current participation in another research study
* Females who are breastfeeding, pregnant, or with plans to get pregnant during the participation in the study
* Participation in a previous AN2728 clinical trial

Answer: B